Because the in vitro data showed that YB-1 was highly phosphorylated in the different CRC cell lines tested and that the phosphorylation was stimulated by point mutations in KRAS, we tested the phosphorylation status of YB-1 in tumor tissues from three CRC patients. This evidence concerns the gene KRAS and neoplasm.